Literature DB >> 7786833

Effect of beta-blockade on exercise capacity in hypertensive subjects: a one-year double-blind study of celiprolol and metoprolol.

G P Vyssoulis1, M T Kouremetis, M A Valiouli, A P Michaelides, P K Toutouzas.   

Abstract

To assess the effect of beta-blocker antihypertensive therapy on exercise capacity, 40 patients randomized to celiprolol 200 mg and metoprolol 100 mg daily in a double-blind fashion were studied after a month of placebo and a year of active treatment. Both drugs normalized office blood pressure and produced echocardiographic and electrocardiographic left ventricular hypertrophy regression. In symptom-limited maximal stress tests before and after treatment, exercise duration increased with (p < 0.0001) celiprolol (513-700 seconds) and metoprolol (520-634 seconds), although more with the former (p = 0.02). Resting heart rate was reduced with both, more with metoprolol (p < 0.001), while heart rate at peak exercise was reduced similarly with both medications (p < 0.005). Blood pressure at peak exercise was reduced with both celiprolol (217-184 mmHg; p = 0.0002) and metoprolol (218-185 mmHg, p < 0.0001) to a similar degree (p = NS). Exercise parameters were not related to patient age or the degree of left ventricular hypertrophy regression (p = NS). It is concluded that beta-blocker antihypertensive therapy improves exercise capacity, decreasing heart rate and blood pressure responses to stress, irrespective of left ventricular structural changes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7786833     DOI: 10.1007/bf00877753

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  25 in total

1.  Celiprolol in the treatment of hypertension: a comparison with propranolol.

Authors:  S H Taylor; A Beattie; B Silke
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

2.  Left ventricular mass and exercise responses predict future blood pressure. The Muscatine Study.

Authors:  L T Mahoney; R M Schieken; W R Clarke; R M Lauer
Journal:  Hypertension       Date:  1988-08       Impact factor: 10.190

3.  Increased cardiac output and lowered peripheral resistance during metoprolol treatment.

Authors:  J Wikstrand; B Trimarco; G Buzzetti; B Ricciardelli; N de Luca; M Volpe; M Condorelli
Journal:  Acta Med Scand Suppl       Date:  1983

4.  Assessment of left-ventricular mass and its response to antihypertensive treatment.

Authors:  D B Rowlands; D R Glover; M A Ireland; R A McLeay; T J Stallard; R D Watson; W A Littler
Journal:  Lancet       Date:  1982-02-27       Impact factor: 79.321

5.  Comparison of ketanserin and celiprolol on regression of left ventricular hypertrophy in older hypertensive patients.

Authors:  G P Vyssoulis; E A Karpanou; C E Pitsavos; T K Kourtis; A A Paleologos; P K Toutouzas
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

6.  Echocardiographic left ventricular hypertrophy as related to arterial pressure and plasma norepinephrine concentration in arterial hypertension. Reversal by atenolol treatment.

Authors:  L Corea; M Bentivoglio; P Verdecchia
Journal:  Hypertension       Date:  1983 Nov-Dec       Impact factor: 10.190

7.  Exercise systolic blood pressure: a powerful determinant of increased left ventricular mass in patients with hypertension.

Authors:  J F Ren; A H Hakki; M N Kotler; A S Iskandrian
Journal:  J Am Coll Cardiol       Date:  1985-05       Impact factor: 24.094

8.  Factors influencing cardiac hypertrophy in hypertensive patients.

Authors:  M M Ibrahim; M A Madkour; R Mossallam
Journal:  Clin Sci (Lond)       Date:  1981-12       Impact factor: 6.124

9.  Importance of ancillary properties of beta blockers in angina: a study of celiprolol and atenolol.

Authors:  J M McLenachan; J T Wilson; H J Dargie
Journal:  Br Heart J       Date:  1988-06

10.  24-h ambulatory non-invasive blood pressure monitoring in the assessment of the antihypertensive action of celiprolol.

Authors:  G Parati; G Pomidossi; R Casadei; A Ravogli; S Trazzi; E Mutti; G Mancia
Journal:  J Int Med Res       Date:  1988       Impact factor: 1.671

View more
  2 in total

Review 1.  Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.

Authors:  C J Dunn; C M Spencer
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

2.  Candesartan improves maximal exercise capacity in hypertensives: results of a randomized placebo-controlled crossover trial.

Authors:  Maria Leonarda De Rosa; Massimo Chiariello
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-04       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.